Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
Ray et al., Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single.., medRxiv, doi:10.1101/2020.11.25.20237883
Small RCT 80 hospitalized patients in India, 40 treated with convalescent plasma, not showing significant differences in primary analysis. Authors note that significant improvement in hypoxia, reduction in hospital stay, and survival benefit was seen in severe COVID-19 patients with ARDS aged <67. CTRI/2020/05/025209.
risk of death, 33.0% lower, HR 0.67, p = 0.34, treatment 10 of 40 (25.0%), control 14 of 40 (35.0%), NNT 10, adjusted per study, Mantel-Haenszel, primary outcome.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20237883; this version posted November 29, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Clinical and immunological benefits of convalescent
plasma therapy in severe COVID-19: insights from a
single center open label randomised control trial
Yogiraj Ray1,2*, Shekhar Ranjan Paul1, Purbita Bandopadhyay3, Ranit D’Rozario3,
Jafar Sarif3, Abhishake Lahiri4, Debaleena Bhowmik4, Janani Srinivasa
Vasudevan5, Ranjeet Maurya5, Akshay Kanakan5, Sachin Sharma5, Manish
Kumar5, Praveen Singh5, Rammohan Roy1, Kausik Chaudhury1, Rajsekhar
Maiti1,6, Saugata Bagchi1, Ayan Maiti1, Md. Masoom Perwez1, Abhinandan
Mondal1, Avinash Tewari1, Samik Mandal1, Arpan Roy1, Moumita Saha1, Durba
Biswas7, Chikam Maiti7, Sayantan Chakraborty8, Biswanath Sharma Sarkar1,
Anima Haldar1, Bibhuti Saha2, Shantanu Sengupta5, Rajesh Pandey5, Shilpak
Chatterjee3, Prasun Bhattacharya7, Sandip Paul4, Dipyaman Ganguly3*.
1
2
Infectious Disease & Beleghata General Hospital, Kolkata, India
Department of Tropical Medicine, School of Tropical Medicine, Kolkata, India
3
IICB-Translational Research Unit of Excellence, CSIR-Indian Institute of Chemical Biology,
Kolkata, India
4
Division of Structural Biology & Bioinformatics, CSIR-Indian Institute of Chemical Biology,
Kolkata, India
5
CSIR-Institute of Genomics and Integrative Biology, Delhi, India
6
Department of Pediatrics, Sagar Dutta Hospital & College of Medicine, Kolkata, India
7
Department of Immunohematology & Blood Transfusion, Medical College Hospital, Kolkata,
India
8
Department of Critical Care Medicine, Tata Medical Center, Kolkata, India.
*Correspondence: Dipyaman@iicb.res.in, jaggs.nbmc@gmail.com
1
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.11.25.20237883; this version posted November 29, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Abstract
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.